CYP19A1 and non-small cell lung carcinoma: Biomarker studies from a Phase 1b trial with aromatase inhibitor exemestane showed that the overall response rate was correlated with tumor aromatase expression in postmenopausal women with stage IV non-squamous NSCLC, and the use of exemestane was well-tolerated [144].